port
Exactly. GSK have only ever spent money on relenza when needed. To be doing this they have the numbers to back it.
No doubt about it. They have no love for relenza but money talks.
All this creates all sorts of scenarios. Maybe antivirals are a better option for virus control instead of expensive vaccines that can be are rendered useless quite quickly.
The world of a new outlook on antivirals may be approaching. Go Lani.